All News
We are truly blessed to live in an era when response to RA treatment is the norm.
(our forefathers looking on jealously from their gold and pencillinamine towers!)
real-world data from BIOBADASER registry OP0123 #EULAR2021 @RheumNow https://t.co/RuQkK1ZXZv
David Liew drdavidliew ( View Tweet)
tofa/bari in RA H2H vs TNFi comparative efficacy studies highlighted (more head-to-head studies please!) @karolinskainst OP0122 #EULAR2021 @RheumNow (also Swedish national registry data showed tofa/bari comparable to non-TNFi bDMARDs, but no photos allowed!) https://t.co/CUWlK2O94h
David Liew drdavidliew ( View Tweet)
VTE/VZV in baricitinib & tofacitinib seem unrelated to on-target effects.
Is there VTE/VZV-related off-target culpable binding?
Computer (AI) says no, but...
bari binds PDE10A2 (an antipsychotic target), lab confirmed. Missing link to reduced pain?
POS0091 #EULAR2021 @RheumNow https://t.co/uqYixHhW1z
David Liew drdavidliew ( View Tweet)
Our SLR on pathogenesis of SARS-CoV-2 Main findings: TH1 cytokines and IL-6 associated w/ severe COVID19 and fatal outcomes. ⬆️ classical blood monocytes and polyfunctional T cells. Impaired IFN response associated w/ poor outcomes. #POS0052 @Rheumnow #EULAR2021 @alessia_alunno https://t.co/PGph5IRBkX
Aurelie Najm AurelieRheumo ( View Tweet)
Each line is a different country's JAK inhibitor for RA registry, looking at drug stopped for adverse events.
Why all the variation?
(Until we sort that out, we'll struggle to assess JAKi post-marketing safety...)
@k_lauper's JAK-pot study POS0093 #EULAR2021 @RheumNow https://t.co/YykoG7LlEw
David Liew drdavidliew ( View Tweet)
German SpA Inception Cohort analyses: TNFi assc w/ ⬇️ sacroiliitis and spinal dz progression in axSpA pts, but the effect is evident starting between 2 and 4 years post tx induction. #EULAR2021 Abstracts #OP0137 & #OP0139 @RheumNow https://t.co/uR9rug6zqI https://t.co/xF3wcxm4cf https://t.co/lEsUvOSJ6K
Dr. Rachel Tate uptoTate ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, Janssen. All content chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
@jeffsparks wahooo! Congrats on the #EULAR2021 clinical science award recognition!
Dr. Rachel Tate uptoTate ( View Tweet)
#EULAR2021 #EULAR21 #eular #spondyloarthritis
I have always thought we named nr-axSPA wrongly - Tends to trivialise its gravity and importance
Shouldn’t it be our goal to diagnose all SpA at the nr-axSPA stage
@deodhara @NigilHaroon https://t.co/zwKI1o9WcO
EnvisionRheumat ERheumat ( View Tweet)
Patient profiles have changed in clinical trials of PsA #EULAR2021 https://t.co/6l2RfOPkSq
Dr Irwin Lim _connectedcare ( View Tweet)
#EULAR2021: AxSpA patients with greater patient-reported pain and spinal pain relative to axPsA patients among real-world patients in CorEVitas' Psa/Spa observational Registry per Dr. Mease's oral abstract presentation. @RheumNow https://t.co/YEdhd7x6cb
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#EULAR2021 - Key points from Dr. Mease's oral abstract:
⭐️AxSpA pts were younger & more likely to be male & have a hx of uveitis & IBD
⭐️AxSpA pts had less exposure to prior therapies relative to axPsA pts
⭐️AxSpA assoc w/ > spinal pain regardless of b/tsDMARD status
@Rheumnow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#EULAR2021: AxSpA patients more likely to experience IBD and uveitis whereas axPsA more likely to experience dactylitis and enthesitis per Dr. Philip Mease's study among real-world patients in CorEVitas' Psa/Spa Registry.
@RheumNow https://t.co/g2m5fylFJj
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#EULAR2021: SpA pts w/ predominant axial phenotype tended to be HLAB27+ & have uveitis whereas those w/ predom peripheral phenotype tended to have arthritis, dactylitis, or psoriasis & fit a clinical dx of axSpA & psSpa (incl psA) respectively per this observat study. @RheumNow https://t.co/E5UTbc6Sqb
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#EULAR2021 bDMARD and TNF-i naive patients w/ r-axSpA without evidence of objective inflammation (normal CRP & MRI ) showed ASA40 response w/ ixekizumab @RheumNow https://t.co/5KT8A81auq
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#OP0089 Do you know the pain catastrophizing score #PCS ? Cross-sectional study of 1199 #RA, #PsA & #ax-SpA patients: Low PCS were more often in remission as high PCS in RA & ax-SpA. PCS was associated with remission rates in RA and ax-SpA, but not in PsA #EULAR2021 @RheumNow https://t.co/MYiLmPPbDN
Paul Studenic Stiddyo ( View Tweet)
#EULAR2021: "I am an advocate for smart T2T, not a mathematical T2T approach." - Dr. Filip van den Bosch @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#EULAR2021: In India, some of the JAKi are costing less than $30/mo per a EULAR participant! Dr. Filip van den Bosch does not recommend using tofacitinib as a diagnostic tool for SpA over NSAIDs even if it is so cheap. @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#EULAR2021: Reduced likelihood of reaching disease remission in patients with RA or PsA who have concomitant depression and anxiety per prospective NOR-DMARD study. Social state and mental health factors play an important role in noresponse in T2T approach. @RheumNow https://t.co/Vl0Xkz2SNF
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#EULAR2021: Dr. Filip van den Bosch recommends the "DEER" treatment approach for SpA: Dedicated Empathic and Educated Rheumatologist! @RheumNow https://t.co/W0jbGXk7q8
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
